Zoetis Inc. announced that Dectomax-CA1 Injectable (doramectin injection) is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls. Dectomax and Dectomax-CA1 Injectable for use in cattle have a 35-day pre-slaughter withdrawal period.
Livestock producers are encouraged to work closely with their herd veterinarian to implement strategic prevention and control measures.
Source: AgriMarketing, October 1, 2025. Link. Dectomax-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under NADA 141-616.